Kintor Pharma-B (09939): Long-term safety clinical trial of KX-826 tincture 1.0% for androgenetic alopecia in Chinese adult males completed

Zhito Finance APP news, Kintor Pharmaceutical-B (09939) announced that its independently developed, potentially first-in-class KX-826 tincture 1.0% for the treatment of androgenetic alopecia ("AGA" or "hair loss") long-term safety clinical trial ("this long-term safety clinical trial") has completed all subject follow-ups, demonstrating a favorable safety profile.